NasdaqCM - Nasdaq Real Time Price USD

Genelux Corporation (GNLX)

2.9600
+0.1100
+(3.86%)
At close: May 9 at 4:00:01 PM EDT
2.9600
0.00
(0.00%)
After hours: May 9 at 4:05:09 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
8
8
170
11,068
0
Operating Expense
31,704
31,704
24,335
14,081
14,613
Operating Income
-31,696
-31,696
-24,165
-3,013
-14,613
Net Non Operating Interest Income Expense
1,457
1,457
-3,730
-1,408
-1,815
Other Income Expense
370
370
-402
314
50
Pretax Income
-29,869
-29,869
-28,297
-4,107
-16,378
Tax Provision
--
--
0
1,100
0
Net Income Common Stockholders
-29,869
-29,869
-28,297
-5,207
-16,378
Diluted NI Available to Com Stockholders
-29,869
-29,869
-28,297
-5,207
-16,378
Basic EPS
-0.95
--
-1.16
-0.22
-0.69
Diluted EPS
-0.95
--
-1.16
-0.22
-0.69
Basic Average Shares
31,450.7270
--
24,429.2780
23,647.4420
23,647.4420
Diluted Average Shares
31,450.7270
--
24,429.2780
23,647.4420
23,647.4420
Total Operating Income as Reported
-31,696
-31,696
-24,165
-3,013
-14,613
Total Expenses
31,704
31,704
24,335
14,081
14,613
Net Income from Continuing & Discontinued Operation
-29,869
-29,869
-28,297
-5,207
-16,378
Normalized Income
-30,239
-30,239
-27,895
-5,455.0600
-16,428
Interest Income
1,457
1,457
244
0
--
Interest Expense
0
0
822
1,408
1,417
Net Interest Income
1,457
1,457
-3,730
-1,408
-1,815
EBIT
-29,869
-29,869
-27,475
-2,699
-14,961
EBITDA
-28,966
-28,966
-26,457
-1,731
-14,066
Reconciled Depreciation
903
903
1,018
968
895
Net Income from Continuing Operation Net Minority Interest
-29,869
-29,869
-28,297
-5,207
-16,378
Total Unusual Items Excluding Goodwill
370
370
-402
314
50
Total Unusual Items
370
370
-402
314
50
Normalized EBITDA
-29,336
-29,336
-26,055
-2,045
-14,116
Tax Rate for Calcs
0
0
0
0.0002
0
Tax Effect of Unusual Items
0
0
0
65.9400
0
12/31/2021 - 1/26/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SABS SAB Biotherapeutics, Inc.
1.7900
+3.47%
 
DSGN Design Therapeutics, Inc.
3.5000
-0.57%
 
ERAS Erasca, Inc.
1.3900
0.00%
 
ALLR Allarity Therapeutics, Inc.
1.0500
-1.87%
 
GLUE Monte Rosa Therapeutics, Inc.
4.0900
-3.08%
 
REPL Replimune Group, Inc.
7.71
-0.77%
 
BCDA BioCardia, Inc.
2.8500
0.00%
 
FHTX Foghorn Therapeutics Inc.
4.2000
-7.28%
 
MGTX MeiraGTx Holdings plc
5.42
-0.91%
 
ADAG Adagene Inc.
1.6000
+0.63%